Scan-associated Distress May Be Persistent for Patients With NSCLC

Share this content:
Scan-associated distress, which is commonly experienced by patients with non-small cell lung cancer (NSCLC), may impair quality of life.
Scan-associated distress, which is commonly experienced by patients with non-small cell lung cancer (NSCLC), may impair quality of life.

Scan-associated distress, which is commonly experienced by patients with non-small cell lung cancer (NSCLC), may impair quality of life, according to a study published in the journal Lung Cancer.1

Researchers identified risk factors for scan-associated distress among patients with NSCLC, and assessed the impact of this distress on quality of life.

Investigators surveyed 103 patients with recurrent/metastatic NSCLC treated at an academic medical center. Clinical and demographic data were obtained from patient chart records and self-reports.

A modified version of the Impact of Event Scale 6 (IES-6) and the Functional Assessment of Cancer Therapy – Lung (FACT-L) were used to assess scan-associated distress and quality of life, respectively.

Among the respondents, 72.8% discussed a recent scan at the study visit and 83% reported some scan-associated distress.

Scan-associated distress was associated with impaired quality of life (P = .004), with each unit increase in the IES-6 score corresponding to about a 1-unit reduction in FACT-L score.

RELATED: Leptomeningeal Metastases More Common in Patients With EGFR Mutations

Scan-associated distress was not, however, associated with time since diagnosis, whether the patient had a recent scan, or progressive disease.                           

Reference

  1. Bauml JM, Troxel A, Epperson CN, et al. Scan-associated distress in lung cancer: Quantifying the impact of “scanxiety." Lung Cancer. 2016 Aug 16. doi: 10.1016/j.lungcan.2016.08.002 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters